ATH-1105 prolongs survival in mouse model of ALS
ATH-1105, a treatment candidate by Athira Pharma, significantly prolonged survival in a mouse model of amyotrophic lateral sclerosis…
Articles by Lindsey Shapiro, PhD
Qalsody’s conditional OK for genetic cause of ALS hailed as new ‘option’
The recent conditional approval of Qalsody (tofersen) for adults with amyotrophic lateral sclerosis (ALS) who carry mutations in…
AAN 2023: Memantine fails to slow disease progression in Phase 2b trial
Daily oral treatment with memantine did not slow disease progression nor did it reduce biomarker changes among people with…
Arrowhead to seek OK later this year to test RNA therapy for ALS
Arrowhead Pharmaceuticals will seek permission later this year for the first clinical trial of ARO-SOD1, its RNA-based therapy for…
Post-marketing trial of 2 Radicava ORS doses now fully enrolled
A Phase 3b study evaluating the long-term safety and effectiveness of two dosing regimens of Radicava ORS (edaravone) —…
BrainStorm nets NurOwn ADCOM meeting over FDA objections
The U.S. Food and Drug Administration (FDA) will hold an advisory committee meeting to discuss BrainStorm Cell Therapeutics‘ application…
CNM-Au8 found to delay clinical worsening in ALS HEALEY trial
Treatment with CNM-Au8 significantly delayed clinical worsening in people with amyotrophic lateral sclerosis (ALS), according to new exploratory…
Slower ALS progression seen with long-term CNM-Au8 use in trial
Amyotrophic lateral sclerosis (ALS) patients treated earlier with CNM-Au8 in a clinical trial experienced a significantly slower disease…
Early stress pathway activation combats cell death in FUS-ALS
Early activation of certain cellular stress response pathways may help prevent the death of motor neurons in amyotrophic lateral…
Exploratory Phase 2 clinical trial of EPI-589 for ALS is ongoing
A small Phase 2 clinical trial is evaluating the safety and tolerability of investigational treatment candidate EPI-589 in adults with…